BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Connect Biopharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Connect Biopharma's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06488755-1328@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rademikibart: Phase 3 readout est. (NCT06488755)
DESCRIPTION:Rademikibart\, phase 3\, Asthma.\nStudy: SIM0718 Treatment of A
 sthma Clinical Study\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rademikibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06488755
URL:https://assetmemo.bio/drug/rademikibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
